Hayes P E, Schulz S C
Department of Pharmacy and Pharmaceutics, Virginia Commonwealth University, Medical College of Virginia, Richmond 23298.
J Affect Disord. 1987 Sep-Oct;13(2):119-30. doi: 10.1016/0165-0327(87)90017-6.
Studies evaluating the antianxiety and antipanic properties of beta-blockers do not support their routine use in treating either generalized anxiety disorder or panic disorder. The use of propranolol for anxiety disorders accompanied by physical symptoms, especially cardiovascular complaints, may be effective in some patients when combined with benzodiazepines or perhaps in some non-responders to conventional treatment. Better designed studies are needed to evaluate the exact role of beta-blocking agents in treating anxiety. The efficacy of propranolol in patients with panic disorder has not been widely researched, but preliminary results have not been encouraging. Propranolol may provide symptomatic relief in some patients with residual somatic complaints (i.e., palpitations and tachycardia), when combined with the patient's ongoing drug regimen. Because beta-blockers may induce depression, they should be used cautiously--if at all--in panic patients with concurrent depressive illness.
评估β受体阻滞剂抗焦虑和抗惊恐特性的研究并不支持其在治疗广泛性焦虑症或惊恐障碍中的常规使用。对于伴有身体症状（尤其是心血管方面主诉）的焦虑症患者，使用普萘洛尔时，与苯二氮䓬类药物联合使用，或者在某些对传统治疗无反应的患者中使用，可能对部分患者有效。需要开展设计更优的研究来评估β受体阻滞剂在治疗焦虑症中的确切作用。普萘洛尔在惊恐障碍患者中的疗效尚未得到广泛研究，但初步结果并不令人鼓舞。当与患者正在使用的药物治疗方案联合使用时，普萘洛尔可能会使一些有残留躯体主诉（即心悸和心动过速）的患者症状得到缓解。由于β受体阻滞剂可能诱发抑郁，对于同时患有抑郁症的惊恐障碍患者，应谨慎使用（若要使用的话）。
